H A R E S I G N

Primary care management consulting for GP practices and PCNs across England. IGPM Accredited Member.

Contact Info
Email

[email protected]

Connect

LinkedIn

Primary care consulting for GP practices & PCNs across England. Get in touch →

Get In Touch

QOF Income Calculator

Select a Practice

Search by practice name or ODS code. Select a year to see income estimates, charts, domain summaries, and exports.

What's Changed in 2026/27

Total QOF points rise to 582: clinical domain 437 pts, public health 145 pts

Maximum income ceiling updated across all indicators

CHD and STIA blood pressure indicators retired; replaced by CD001 and CD002

Secondary-prevention BP income now modelled under the cardiovascular disease domain

Four new indicators introduced: HF009, DM037, OB004 and OB005

All four appear in the indicator table with full income and threshold modelling

DM034 and DM035 carry increased point values; CHOL003 reduced to 20 points

Point totals and maximum income figures updated to reflect revised weightings

VI001–VI003 now offer an improvement-payment route alongside the standard threshold

Threshold column shows both payment routes; income is modelled on the standard route

NDH003 replaces NDH002, expanding the register to include previous gestational diabetes patients

Indicator code and description updated; income modelled under the revised register definition

Income = Points × £/point × CPI × ADF × Achievement Fraction

National Reference

2026/27

Select a practice above to calculate CPI- and ADF-adjusted figures. Until then, this reference table shows each indicator and a national-average income estimate based on the published £/point rate.

Indicator Domain Description Points Threshold National Avg Income Estimate
AF006 clinical Patients with atrial fibrillation in whom stroke risk has been assessed using CHA2DS2-VASc in the preceding 12 months (excluding those with a previous score of 2 or more). 12 40-95% £2,735.40
BP002 public health Patients aged 45 or over who have a record of blood pressure in the preceding 5 years. 15 50-90% £3,419.25
AF008 clinical Patients on the AF register with CHA2DS2-VASc score of 2 or more, prescribed a DOAC or, if unsuitable/declined, a Vitamin K antagonist. 12 70-95% £2,735.40
SMOK002 public health Patients with specified long-term conditions whose notes record smoking status in the preceding 12 months. 25 50-90% £5,698.75
CHD005 clinical Patients with coronary heart disease with a record in the preceding 12 months that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken. 7 56-96% £1,595.65
SMOK004 public health Patients aged 15 or over recorded as current smokers who have a record of offer of support and treatment within the preceding 24 months. 12 40-90% £2,735.40
CD001 clinical Patients with CHD, stroke or TIA, aged 79 years or under, without moderate or severe frailty, whose last BP in the preceding 12 months is 140/90 mmHg or less (or equivalent home BP). 41 40-90% £9,345.95
VI001 public health Babies reaching 8 months in the preceding 12 months who received at least 3 doses of a diphtheria, tetanus and pertussis containing vaccine before age 8 months. 18 89-96% (or improvement 5-18 percentage points) £4,103.10
CD002 clinical Patients with CHD, stroke or TIA, aged 80 years or over, without moderate or severe frailty, whose last BP in the preceding 12 months is 150/90 mmHg or less (or equivalent home BP). 20 46-90% £4,559.00
VI002 public health Children reaching 18 months in the preceding 12 months who received at least 1 dose of MMR or MMRV between ages 12 and 18 months. 18 86-96% (or improvement 5-23 percentage points) £4,103.10
CHOL003 clinical Patients on the CHD, PAD, Stroke/TIA or CKD register currently prescribed a statin or, if declined/unsuitable, another lipid-lowering therapy. 20 70-95% £4,559.00
VI003 public health Children reaching 5 years in the preceding 12 months who received a second dose of MMR or MMRV before age 5 years. 18 81-96% (or improvement 5-30 percentage points) £4,103.10
CHOL004 clinical Patients on the CHD, PAD or Stroke/TIA register with most recent cholesterol in the preceding 12 months at target (LDL ≤2.0 or non-HDL ≤2.6 mmol/L). 44 20-50% £10,029.80
VI004 public health Patients who reached 80 years old in the preceding 12 months who have received shingles vaccine between ages 70 and 79 years. 10 50-60% £2,279.50
HF008 clinical Patients with heart failure diagnosed on or after 1 April 2023, confirmed appropriately by echocardiogram or specialist assessment. 6 50-90% £1,367.70
OB004 public health Adults living with obesity referred to a weight management programme in the QOF year. 5 10-30% £1,139.75
HF007 clinical Patients with heart failure on the register who have had a review in the preceding 12 months including functional capacity and medication review. 7 50-90% £1,595.65
OB005 public health Adults living with obesity eligible for shared decision-making and pharmacotherapy pathway support. 13 50-80% £2,963.35
CS005 public health Women/people with a cervix aged 25–49 with adequate cervical screening test in the previous 3 years and 6 months. 7 45-80% £1,595.65
HF009 clinical Patients with HFrEF currently treated with four-pillar therapy: ACEi/ARNI/ARB, beta blocker, MRA and SGLT2 inhibitor. 12 20-50% £2,735.40
CS006 public health Women/people with a cervix aged 50–64 with adequate cervical screening test in the previous 5 years and 6 months. 4 45-80% £911.80
HYP010 clinical Patients with hypertension aged 79 years or under, without moderate or severe frailty, whose last BP in the preceding 12 months is 140/90 mmHg or less (or equivalent home BP). 38 40-85% £8,662.10
HYP011 clinical Patients with hypertension aged 80 years or over, without moderate or severe frailty, whose last BP in the preceding 12 months is 150/90 mmHg or less (or equivalent home BP). 14 40-85% £3,191.30
STIA007 clinical Patients with non-haemorrhagic stroke or history of TIA who have a record in the preceding 12 months that an anti-platelet agent or anti-coagulant is being taken. 4 57-97% £911.80
DM006 clinical Patients with diabetes, on the register, with a diagnosis of nephropathy (clinical proteinuria) or micro-albuminuria who are currently treated with an ACE-I (or ARBs). 3 57-97% £683.85
DM014 clinical Patients newly diagnosed with diabetes who have a record of referral to a structured education programme within 9 months of entry on to the register. 11 40-90% £2,507.45
DM020 clinical Patients with diabetes whose latest IFCC-HbA1c in the preceding 12 months is 58 mmol/mol or less. 17 35-75% £3,875.15
DM021 clinical Patients with diabetes, on the register, with moderate or severe frailty in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months. 10 52-92% £2,279.50
DM034 clinical Patients with diabetes and no CVD currently prescribed a statin, or where clinically unsuitable/declined, another lipid-lowering therapy. 8 50-90% £1,823.60
DM035 clinical Patients with diabetes and established CVD currently prescribed a statin, or where clinically unsuitable/declined, another lipid-lowering therapy. 8 50-90% £1,823.60
DM036 clinical Patients with diabetes, on the register aged 79 years and under, without moderate or severe frailty, whose last BP in the preceding 12 months is 140/90 mmHg or less (or equivalent home BP). 27 38-90% £6,154.65
DM037 clinical Patients with diabetes receiving all eight annual care processes in the preceding 12 months. 10 35-75% £2,279.50
AST007 clinical Patients with asthma on the register who have had an asthma review in the preceding 12 months that includes an assessment of asthma control, a recording of the number of exacerbations, an assessment of inhaler technique and a written personalised action plan. 20 45-70% £4,559.00
AST012 clinical Patients with a new diagnosis of asthma on or after 1 April 2025 with a record of an objective test between 3 months before or 3 months after diagnosis. 15 45-80% £3,419.25
COPD010 clinical Patients with COPD who have had a review in the preceding 12 months including exacerbation count and MRC breathlessness score. 9 50-90% £2,051.55
DEM004 clinical Patients with dementia who have had a face-to-face or remote care plan review in the preceding 12 months. 14 35-70% £3,191.30
MH002 clinical Patients with schizophrenia, bipolar affective disorder and other psychoses with a comprehensive care plan documented in the preceding 12 months. 5 40-90% £1,139.75
MH003 clinical Patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood pressure in the preceding 12 months. 3 50-90% £683.85
MH006 clinical Patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of BMI in the preceding 12 months. 3 50-90% £683.85
MH007 clinical Patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of alcohol consumption in the preceding 12 months. 3 50-90% £683.85
MH011 clinical Patients with schizophrenia, bipolar affective disorder and other psychoses with lipids recorded in the preceding 12 months. 7 50-90% £1,595.65
MH012 clinical Patients with schizophrenia, bipolar affective disorder and other psychoses with glucose or HbA1c recorded in the preceding 12 months. 7 50-90% £1,595.65
NDH003 clinical Patients with non-diabetic hyperglycaemia or previous gestational diabetes who have had HbA1c or fasting blood glucose in the preceding 12 months. 20 50-90% £4,559.00